From the clinical translational perspective, the present study suggests that Meox1/Cthrc1/p-Smad2/3 signaling pathway is a promising prognostic and therapeutic target for post-MI cardiac fibrosis and heart failure. The gene discussed is SMAD2; the disease is heart failure.